Corcept beats Q2 estimates, raises 2026 outlook on Lifyorli launch

Key Takeaways:

Corcept reported Q2 EPS of $0.36, beating consensus estimates of a $0.04 loss
Revenue rose 32% to $256.1M, driven by Korlym growth and the Lifyorli launch
Full-year 2026 revenue guidance raised to $1.1B-$1.2B from $950M-$1.05B

Corcept Therapeutics reported second-quarter earnings of 36 cents per share, beating the consensus estimate of a 4-cent loss, as newly approved ovarian cancer drug Lifyorli (relacorilant) generated $47.6 million in its first full quarter on the market.

"The Lifyorli launch has exceeded our expectations, with more than 1,300 patients starting treatment and over 1,000 physicians prescribing the drug in its first quarter," management said on the earnings call. The regimen was listed as a preferred option in the NCCN Guidelines shortly after its March 2026 approval.

Revenue reached $256.1 million, up 32% from a year earlier and surpassing the $216 million consensus. Cushing's syndrome drug Korlym contributed $208.6 million, up 7.3% year over year, while Lifyorli added $47.6 million — well above the $2 million analysts had modeled for its first quarter of availability. Operating expenses rose 28.1% to $214.8 million, reflecting launch-related spending, with SG&A climbing 51.1% to $156.9 million and R&D declining 10.9% to $53.9 million.

The raised guidance signals management expects both the endocrinology and oncology franchises to sustain momentum. Corcept now sees 2026 revenue of $1.1 billion to $1.2 billion, up from a prior range of $950 million to $1.05 billion. The company ended the quarter with $544.6 million in cash and investments. Shares have surged 167.1% year to date, and the stock jumped 17.4% following the report.

Pipeline catalysts ahead

Corcept resubmitted its new drug application for relacorilant in Cushing's syndrome to the FDA in June, with a target action date of Dec. 17, 2026. The filing is supported by data from the GRACE study and confirmatory evidence from the phase III GRADIENT trial. In Europe, a marketing authorization application for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer is under review, with a decision expected by year-end.

The company is also evaluating relacorilant in combination with nab-paclitaxel and bevacizumab in the phase II BELLA study for platinum-resistant ovarian cancer, with top-line data due by the end of 2026. Additional studies across platinum-sensitive ovarian, endometrial, cervical and pancreatic cancers are on track to report results by the end of 2027.

Beyond relacorilant, Corcept is advancing dazucorilant in amyotrophic lateral sclerosis and miricorilant in metabolic dysfunction-associated steatohepatitis. The phase IIb MONARCH study of miricorilant in MASH has completed enrollment, with results expected by year-end.

What this means for holders

The guidance raise and Lifyorli's rapid uptake suggest Corcept's revenue base is diversifying beyond its Cushing's syndrome franchise. Investors will watch the Dec. 17 PDUFA date for relacorilant in Cushing's syndrome and the BELLA study readout as the next major catalysts.

This article is for informational purposes only and does not constitute investment advice.